96805 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses; RNA viruses; Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus; Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV; HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
STEM CELL BASED DELIVERY OF TUMOR-SPECIFIC RETROVIRAL VECTORS
#2DELIVERY OF HETEROLOGOUS PROTEINS
#3METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR
#4COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
#5RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION
#6HIV-1 ENVELOPE STABILIZING MUTATIONS
#7GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE
#8IMMUNOGENIC TRIMERS
#9METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR
#10SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES
#11RAPID ELICITATION OF BROADLY NEUTRALIZING BOVINE ANTIBODIES TO HIV ENV
#12COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
#13CLD PROTEIN MUTANT AND APPLICATION THEREOF
#14NEW ADJUVANT TO IMPROVE THE INNATE IMMUNITY
#15METHODS AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
#16Compositions and methods for promoting immune responses to human immunodeficiency virus
#17HIV VACCINE COMPOSITIONS, METHODS, AND USES THEREOF
#18Methods and reagents for assessing the presence or absence of replication competent virus
#19SCAFFOLDED HIV-1 VACCINE IMMUNOGENS
#20METHODS AND COMPOSITIONS RELATED TO HIV-1 NANOPARTICLE VACCINES WITH IMPROVED PROPERTIES
#21IMMUNOGENIC TRIMERS
#22FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY
#23POLYPEPTIDES MIMICKING EPITOPE OF BROADLY NEUTRALIZING ANTIBODY VRC01 AS ANTIGENS FOR A VACCINE PREVENTING HIV-1 INFECTION
#24COMPOSITIONS AND METHODS BASED ON HIV GP120 MUTANTS
#25Trimer stabilizing HIV envelope protein mutations
#26Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#27Multivalent HIV vaccine boost compositions and methods of use
#28HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
#29HIV vaccination compositions comprising vaccinia VLPS and plant-produced VLPS presenting HIV antigens
#30COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
#31HIV-1 envelope stabilizing mutations
#32Recombinant HIV Env polypeptides and their use
#33FERRITIN NANOPARTICLE DISPLAYING AN HIV TRIMER
#34Recombinant gp120 protein with V1-loop deletion
#35Non-Signaling HIV Fusion Inhibitors And Methods Of Use Thereof
#36STABILIZED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (ENV) TRIMER VACCINES AND METHODS OF USING SAME
#37Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof
#38Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
#39Self-assembling insect ferritin nanoparticles
#40Recombinant HIV-1 envelope proteins and their use
#41Methods and compositions for cellular immunotherapy
#42Methods and reagents for assessing the presence or absence of replication competent virus
#43Mosaic HIV-1 envelopes to induce ADCC responses
#44Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein
#45Methods and constructs for production of lentiviral vector
#46Scaffolded HIV-1 Env GP140 trimer immunogen
#47Trimer stabilizing HIV envelope protein mutations
#48Compositions and methods for promoting immune responses to human immunodeficiency virus
#49Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#50MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
#51Rapid elicitation of broadly neutralizing antibodies to HIV Env
#52Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
#53FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY
#54Glycan-masked engineered outer domains of HIV-1 gp120 and their use
#55HIV-1 INCIDENCE BIOMARKERS
#56Stable cell lines for retroviral production
#57Protective Chimeric Antigen Receptor Stem Cell Gene Therapy for Viral Infection
#58Multivalent HIV vaccine boost compositions and methods of use
#59Production of soluble HIV envelope trimers in planta
#60Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
#61Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
#62Method for detecting HIV-1-specific antibodies using clade C env polypeptides
#63Broadly cross-reactive HIV-1-specific antibodies for prevention and treatment of HIV
#64Nucleic acids encoding mosaic conserved region HIV immunogenic polypeptides
#65Scaffolded HIV-1 vaccine immunogens
#66Recombinant HCMV and RHCMV vectors and uses thereof
#67Immunogenic trimers
#68Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
#69Compositions and Methods for Evaluating Viral Receptor/Co-Receptor Usage and Inhibitors of Virus Entry Using Recombinant Virus Assays
#70D-peptide inhibitors of HIV entry and methods of use
#71IMMUNOGENIC COMPOSITIONS
#72Methods and compositions for cellular immunotherapy
#73Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use
#74COMPOSITIONS COMPRISING CH505 ENVELOPES, AND TRIMERS (EIGHT VALENT HIV-1 COMPOSITION AND METHODS)
#75Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag
#76Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
#77Trimer stabilizing HIV envelope protein mutations
#78Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
#79V1/V2 fragments of a HIV-1 envelope glycoprotein
#80Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
#81Soluble HIV-1 envelope glycoprotein trimers
#82Vaccine and therapeutic delivery system
#83Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies
#84Approach to produce HIV-1 GP140 envelope protein trimers
#85Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
#86Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag
#87Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
#88HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof
#89Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
#90Mosaic HIV envelope immunogenic polypeptides
#91Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#92Recombinant HCMV and RHCMV vectors and uses thereof
#93Cyclic HIV-1 Env V3 glycopeptide immunogens
#94Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies
#95Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
#96HIV-1 GP 120 V1/V2 antigens and immunological uses thereof
#97Competitive inhibitor of GP120
#98Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
#99Immunogenic compositions comprising FIV and HIV gag antigens
#100Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
#101Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers
#102GENETIC SIGNATURES IN HIV-1 SUBTYPE C ENVELOPE GLYCOPROTEINS
#103Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
#104Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
#105Recombinant HCMV and RHCMV vectors and uses thereof
#106Vaccine and therapeutic delivery system
#107Broadly cross-reactive HIV-1 Env-specific antibodies
#108MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION
#109Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
#110COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION
#111Method of inhibiting HIV-1 binding to genital epithelia using V3 loop-specific peptides and GP340-specific antibodies
#112Methods for determining the presence of antibodies blocking viral infection
#113Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties
#114Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens
#115Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
#116Mutated HIV Nef for modulating immunity
#117Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
#118Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity
#119Vaccine to pathogenic immune activation cells during infections
#120Tat complexes, and vaccines comprising them